Patents Assigned to Takeda Pharmaceuticals Company Limited
  • Bicyclic compound
    Patent number: 9133129
    Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: October 23, 2012
    Date of Patent: September 15, 2015
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tohru Yamashita, Takuya Fujimoto, Ryo Mizojiri, Kazuko Yonemori, Hideki Hirose, Zenichi Ikeda, Ikuo Fujimori, Kyoko Toyofuku, Tsuneo Yasuma, Nobuyuki Matsunaga
  • PROCESS FOR PRODUCING SOLID PARTICLES
    Publication number: 20150250728
    Abstract: A method of producing crystal of a poorly water-soluble pharmaceutical compound, including mixing a solution of a poorly water-soluble pharmaceutical compound in a good solvent and nanobubble water or an aqueous nanobubble solution to precipitate crystal of the poorly water-soluble pharmaceutical compound. The crystal of a poorly water-soluble pharmaceutical compound obtained by the method is microparticulate and has more uniform particle size distribution, and is superior in the absorbability and sustainability.
    Type: Application
    Filed: September 25, 2013
    Publication date: September 10, 2015
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Naoyuki Murata, Shigeo Yanai
  • Condensed heterocyclic compound
    Patent number: 9120776
    Abstract: The present invention provides a fused heterocyclic compound having an ROR?t inhibitory action. The present invention relates to a compound represented by the formula (I?): wherein each symbol is as defined in the specification, provided that 2-(2-((4-cyanophenyl)amino)-2-oxoethoxy)-N-(9-ethyl-9H-carbazol-3-yl)acetamide and N-(4-cyanophenyl)-N?-(9-ethyl-9H-carbazol-3-yl)-3-methylpentanediamide are excluded, or a thereof.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: September 1, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Satoshi Yamamoto, Junya Shirai, Yoshiyuki Fukase, Yoshihide Tomata, Ayumu Sato, Atsuko Ochida, Kazuko Yonemori, Hideyuki Nakagawa
  • Heterocyclic compound
    Patent number: 9120777
    Abstract: A compound having an SSTR5 antagonist action and use of the compound as a medicament are provided. Specifically, a compound represented by the following formula: wherein each symbol is as defined herein, or a salt thereof, a medicament comprising the compound or a salt thereof, and use of the compound or a salt thereof as an agent the prophylaxis or treatment of diabetes mellitus are provided.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: September 1, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo Kasai, Asato Kina, Hideki Hirose, Takeshi Yamasaki, Tohru Yamashita, Yoichi Nishikawa
  • Fused ring compound and use thereof
    Patent number: 9115136
    Abstract: Provided is a novel compound represented by the following formula wherein each symbol is as defined in the specification, or a salt thereof, which has an angiotensin II receptor antagonistic activity and a peroxisome proliferator-activated receptor ? agonistic activity, and is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and/or metabolic diseases such as diabetes and the like, and the like.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: August 25, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tsuyoshi Maekawa, Hideyuki Igawa
  • Pyrazinooxazepine derivatives
    Patent number: 9115139
    Abstract: Provided is a compound having a serotonin 5-HT2c receptor activating action, useful for lower urinary tract conditions, obesity and cancer. A compound represented by the formula (I0): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: June 14, 2010
    Date of Patent: August 25, 2015
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Shigekazu Sasaki, Tomokazu Kusumoto
  • Fused heteroaromatic pyrrolidinones
    Patent number: 9108970
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: August 18, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yasuyoshi Arikawa, Benjamin Jones, Betty Lam, Christopher Smith, Masashi Takahashi, Qing Dong, Victoria Feher, Zhe Nie
  • FUSED HETEROCYCLIC COMPOUND
    Publication number: 20150225361
    Abstract: A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.
    Type: Application
    Filed: February 11, 2015
    Publication date: August 13, 2015
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Zenichi Ikeda, Minoru Sasaki, Keiko Kakegawa, Fumiaki Kikuchi, Yoichi Nishikawa
  • HETEROCYCLIC COMPOUND
    Publication number: 20150225354
    Abstract: A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.
    Type: Application
    Filed: February 11, 2015
    Publication date: August 13, 2015
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Zenichi Ikeda, Minoru Sasaki, Keiko Kakegawa, Fumiaki Kikuchi, Yoichi Nishikawa
  • 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD
    Publication number: 20150224113
    Abstract: The present invention provides a method of treating acute heart failure by administering a compound of the formula: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 22, 2015
    Publication date: August 13, 2015
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Jason W. Brown, Melinda Davis, Anthony Ivetac, Benjamin Jones, Andre A. Kiryanov, Jon Kuehler, Marion Lanier, Joanne Miura, Sean Murphy, Xiaolun Wang
  • Methods and drug products for treating Alzheimer's disease
    Patent number: 9102666
    Abstract: Provided herein are drug products with low dose pioglitazone for use in the treatment (e.g., delay of onset) of cognitive impairment of the Alzheimer's type. Methods of manufacture thereof are also provided. Further provided are methods of treatment for Alzheimer's disease including administering a drug product with low dose pioglitazone. The methods may include determining whether the subject is at risk of developing Alzheimer's disease based upon the subject's age and TOMM40 523 genotype.
    Type: Grant
    Filed: January 9, 2012
    Date of Patent: August 11, 2015
    Assignees: ZINFANDEL PHARMACEUTICALS, INC., TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Allen D. Roses, Rajneesh Taneja
  • Conjugated anti-CD38 antibodies
    Patent number: 9102744
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: August 11, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • Heterocyclic compound
    Patent number: 9090586
    Abstract: The present invention provides a compound represented by the formula (1): wherein each symbol is as defined in the specification, or a salt thereof, a prodrug of the compound or a salt thereof, a medicament containing the compound or a salt thereof, the medicament which is a phosphodiesterase 10A inhibitor, and a medicament which is for preventing or treating schizophrenia.
    Type: Grant
    Filed: August 3, 2011
    Date of Patent: July 28, 2015
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Masato Yoshikawa, Shinkichi Suzuki, Tomoaki Hasui, Makoto Fushimi, Jun Kunitomo, Haruhi Kamisaki, Takahiko Taniguchi
  • COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT
    Publication number: 20150203464
    Abstract: The present invention provides a medicament that suppresses (or mitigates) various neurological symptoms caused by a peripheral nerve disorder induced by an anti-cancer agent.
    Type: Application
    Filed: April 2, 2015
    Publication date: July 23, 2015
    Applicant: Takeda Pharmaceutical Company Limited
    Inventor: Naomi Kitamoto
  • Heterocyclic compound
    Patent number: 9085578
    Abstract: The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: February 19, 2013
    Date of Patent: July 21, 2015
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Hiroyuki Nagamiya, Masato Yoshida, Masaki Seto, Shogo Marui, Tsuneo Oda, Yuji Ishichi, Hideo Suzuki, Tomokazu Kusumoto, Takatoshi Yogo, Chul Yun Rhim, Cheolhwan Yoon, Gil Nam Lee, Hyun Bin Kang, Kwang Ok Kim, Hye Sun Jeon
  • Fused heterocyclic compound and use thereof
    Patent number: 9079907
    Abstract: The present invention relates to a serotonin 5-HT2C receptor activator containing a compound represented by the formula wherein ring A is a 5- or 6-membered aromatic heterocycle optionally having substituent(s), and ring B is a 7- to 9-membered ring optionally having substituent(s) other than an oxo group wherein the combination of m and n (m,n) is (1,2), (2,1), (2,2), (3,1), (3,2) or (4,1), or a salt thereof or a prodrug thereof, and a fused heterocyclic compound having a serotonin 5-HT2C receptor activating action and the like.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: July 14, 2015
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventor: Izumi Kamo
  • Pyrazolo[4,3-b]pyridine-7-amine inhibitors of ALK5
    Patent number: 9073918
    Abstract: The present invention provides ALK5 inhibitors of the formula wherein the variables are as defined herein. Also provided are pharmaceutical compositions, methods of making the compounds and intermediates thereof; and methods of using the compounds.
    Type: Grant
    Filed: May 10, 2011
    Date of Patent: July 7, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Lily Kwok, John David Lawson, Mark Sabat
  • 5-HT3 RECEPTOR ANTAGONISTS
    Publication number: 20150182533
    Abstract: The present invention provides a method of treating nicotine addiction comprising administering a 5-HT3 receptor antagonists of Formula (I):
    Type: Application
    Filed: March 12, 2015
    Publication date: July 2, 2015
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Stephen Hitchcock, Holger Monenschein, Holly Reichard, Huikai Sun, Shota Kikuchi, Todd Macklin, Maria Hopkins
  • Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
    Patent number: 9066936
    Abstract: The present invention provides a solid pharmaceutical composition containing compound (I) having an angiotensin II receptor antagonistic action and defined in the specification and a pH control agent, which composition is superior in the stability and dissolution property of compound (I).
    Type: Grant
    Filed: March 26, 2008
    Date of Patent: June 30, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shuji Yoneyama, Yutaka Tanoue
  • TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6
    Publication number: 20150175602
    Abstract: The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.
    Type: Application
    Filed: December 19, 2014
    Publication date: June 25, 2015
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Jason Brown, Steve Hitchcock, Maria Hopkins, Shota Kikuchi, Holger Monenschein, Holly Reichard, Kristin Schleicher, Huikai Sun, Todd Macklin